

Prof. Dr. Rüdiger Hehlmann

Director III. Medizinische Klinik, Mannheim



10.5.1941

III. Medizinische Klinik
Medizinische Fakultät Mannheim der
Universität Heidelberg
Wiesbadener Str. 7-11
68305 Mannheim

0621 383 4115 (phone)
0621 383 4201 (fax)
r.hehlmann@urz.uni-heidelberg.de

SCIENTIFIC VITA

- | | |
|------------|--|
| 1969-1970 | Assistant, Max Planck Institute for Biochemistry, Munich |
| 1970 | Research Fellow, University of Rochester, New York, USA |
| 1970-1972 | Research Associate, Columbia University, New York |
| 1972-1973 | Lecturer in Human Genetics and Development at Columbia University |
| 1973-1974 | Intern/Resident, Columbia-Presbyterian Medical Center |
| | Licence to practice Medicine and Surgery in the State of New York |
| 1974 | DFG (German Research Council)-stipend, Memorial Sloan Kettering Cancer Center |
| 1974-1981 | Assistant at the Medizinische Universitätspoliklinik, Munich |
| 1977 | Approval as Internist |
| 1979 | Major Postdoctoral Thesis (Habilitation) |
| 1981-1988 | Tenured Professor (C2) at Munich University |
| since 1982 | Chairman of the German CML-Study Group |
| 1984 | Approval as Hematologist and Oncologist |
| since 1988 | Full Professor of Medicine (C4) at the Mannheim Medical Faculty of the University of Heidelberg and Director of the III. Medizinische Universitätsklinik in Mannheim |
| since 1997 | Secretary General of the International Association for Comparative Research on Leukemia and Related Diseases (IACRLRD) |
| since 1997 | Chairman of the Competence Network "Acute and Chronic Leukemias" |
| 1999-2001 | Dean of the Mannheim Medical Faculty |
| since 2003 | Chairman of the Network of Excellence "European LeukemiaNet" |

AWARDS

Curt-Bohnewand-Prize for cancer research (1984); GSF-Prize for interdisciplinary cooperation (1990); Paul Martini-Prize for improvement of treatment of chronic myeloid leukemia by a new prognostic score (2000). R.T. Silver-Lecture, Cornell University, New York (2004), Honorary Member of the Polish Society for Hematology and Transfusion Medicine (2005), Wiedermann-Lecture, Olmütz, Czechia (2006)

FIELDS OF INTEREST

Mechanisms of carcinogenesis (retroviruses, chemicals, environment); mutation-proliferation vs. chromosomal hypotheses. Diagnosis and therapy of leukemias (CML, chronic myeloproliferative diseases, AML, molecular monitoring). Tyrosine kinase signalling and inhibition; mechanisms of resistance. Clinical trials in hematology and oncology.

SELECTED PUBLICATIONS (SINCE 2000)

Hehlmann R, Hochhaus A, Baccarani M (2007). Seminar Chronic Myeloid Leukemia. Current Management Issues and Recommendations on behalf of the European LeukemiaNet. **Lancet**, in press

Hehlmann R, Berger U, Pfirrmann M, Heimpel H, Hochhaus A, Hasford J, Kolb HJ, Lahaye T, Maywald O, Reiter A, Hossfeld DK, Huber C, Löffler H, Pralle H, Queisser W, Tobler A, Nerl C, Solenthaler M, Goebeler ME, Griesshammer M, Fischer T, Kremers S, Eimermacher H, Pfreundschuh M, Hirschmann WD, Lechner K, Wassmann B, Falge C, Kirchner HH, Gratwohl A, the SAKK and the German CML-Study Group (2007). Drug Treatment is Superior to Allografting as First Line Therapy in Chronic Myeloid Leukemia. **Blood**, Epub 2007 Feb 22

Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, Apperley J, Cervantes F, Cortes J, Deininger M, Gratwohl A, Guilhot F, Horowitz M, Hughes T, Kantarjian H, Larson R, Niederwieser D, Silver R, Hehlmann R (2006). Evolving concepts in the management of chronic myeloid leukemia. Recommendations from an expert panel on behalf of the European LeukemiaNet. **Blood**. 108:1809-20

Hughes TP, Deininger MW, Hochhaus A, Branford S, Radich JP, Kaeda J, Baccarani M, Cortes J, Cross NC, Druker BJ, Gabert J, Grimwade D, Hehlmann R, Kamel-Reid S, Lipton JH, Longtine J, Martinelli G, Saglio G, Soverini S, Stock W, Goldman JM (2006). Monitoring CML patients responding to treatment with tyrosine kinase inhibitors - Review and recommendations for 'harmonizing' current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. **Blood**. 108, 28-37

Reiter A, Walz C, Watmore A, Schoch C, Blau I, Schlegelberger B, Berger U, Telford N, Aruliah S, Yin JA, Vanstraelen D, Barker HF, Taylor PC, O'Driscoll A, Benedetti F, Rudolph C, Kolb HJ, Hochhaus A, Hehlmann R, Chase A, Cross NC (2005). The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2. **Cancer Res** 65, 2662-2667

Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L, Score J, Seear R, Chase AJ, Grand FH, White H, Zoi C, Loukopoulos D, Terpos E, Vervessou EC, Schultheis B, Emig M, Ernst T, Lengfelder E, Hehlmann R, Hochhaus A, Oscier D, Silver RT, Reiter A, Cross NC (2005). Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. **Blood** 106, 2162-2168

Hehlmann R, Berger U, Aul C, Büchner T, Döhner H, Ehninger G, Ganser A, Gökbüget N, Hoelzer D, Überla K, Gassmann W, Ludwig WD, Rieder H, Kneba M, Hochhaus A, Reiter A, Hiddemann W, Ottmann OG, Germing U, Adelhard K, Dugas M, Dirschedl P, Messerer D, Böhme A, Harrison-Neu E, Griesshammer M, Kienast J, Kolb HJ, Ho AD, Hallek M, Neubauer A, Schlegelberger B, Niederwieser D, Heil G, Müller T, Hasford J (2004). The German competence network 'Acute and chronic leukemias'. **Leukemia** 18, 665-669

Hehlmann R, Berger U, Pfirrmann M, Hochhaus A, Metzgeroth G, Maywald O, Hasford J, Reiter A, Hossfeld DK, Kolb HJ, Löffler H, Pralle H, Queisser W, Griesshammer M, Nerl C, Kuse R, Tobler A, Eimermacher H, Tichelli A, Aul C, Wilhelm M, Fischer JT, Perker M, Scheid C, Schenk M, Weiss J, Meier CR, Kremers S, Labeledzki L, Schmeiser T, Lohrmann HP, Heimpel H (2003). Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyurea. **Leukemia** 17, 1529-1537

Fabarius A, Willer A, Yerganian G, Hehlmann R, Duesberg P (2002). Specific aneusomies in Chinese hamster cells at different stages of neoplastic transformation, initiated by nitrosomethylurea. **Proc Natl Acad Sci USA** 99, 6778-83

Duesberg P, Stindl R, Hehlmann R (2001). Origin of multidrug resistance in cells with and without multidrug resistance genes: chromosome reassortments catalyzed by aneuploidy. **Proc Natl Acad Sci USA** 98, 11283-11288